1
Email : info@xynomicpharma.com
Facebook Twitter Google+ Skype Vimeo YouTube
cropped-xynomicpharmalogo-2.jpg
  • Home
    • Privacy Policy
    • Expanded Access
  • Pipeline
  • Management
    • SCIENTIFIC ADVISORY BOARD
      • Anas Younes
      • Glenn Rice
      • Jun Guo
      • Niefang Yu
      • Pamela Munster
    • middle-level management
      • Jerry Meng
    • Y. Mark Xu
    • Jason Wu
    • Sophia Paspal
    • BING ZHAO
  • Media Center
  • Investor Relations
    • Investors
    • Events & Presentations
    • Press Releases
  • Contact Us
  • 中文 (中国)
Latest News
  • wechat-image_20181027000709 Y. Mark Xu talks with CGTN (China Global TV Network) 10/26/2018
  • Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma 09/26/2019
  • Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor 09/26/2019
  • Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors 09/26/2019
  • Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors 09/01/2019
Xynonic Invited to Present at the Prestigious Berstein China Oncology Day in Hong Kong on June 21
05/29/2017 Uncategorized admin

Mr. Y. Mark Xu, Chairman, CEO and President, has been invited to speak at this high profile conference. Other presenting companies include Roche, Sanofi, Hengrui and Sino Biopharm. The venue is Mandarin Oriental Hotel, Hong Kong. This conference is expected to draw attendance of over 100 leading Asian institutional investors and high net worth individuals.

Previous Post Next
Address
  • United States: 13029 Danielson Street, Suite 120, Poway, CA 92064, USA
    China: Suite 3306, K. Wah Centre, 1010 Middle Huaihai Road, Shanghai 200031, China
Links
  • Career
  • Our Policies
Copyright © 2022 Xynomic Pharmaceuticals (Nanjing) Co., Ltd. All Rights Reserved.